Cargando…

An alternate conformation of HCV E2 neutralizing face as an additional vaccine target

To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. E2 is structurally flexible and functions in engaging host recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tzarum, Netanel, Giang, Erick, Kadam, Rameshwar U., Chen, Fang, Nagy, Kenna, Augestad, Elias H., Velázquez-Moctezuma, Rodrigo, Keck, Zhen-Yong, Hua, Yuanzi, Stanfield, Robyn L., Dreux, Marlene, Prentoe, Jannick, Foung, Steven K. H., Bukh, Jens, Wilson, Ian A., Law, Mansun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380959/ https://www.ncbi.nlm.nih.gov/pubmed/32754640 http://dx.doi.org/10.1126/sciadv.abb5642

Ejemplares similares

Genetic and structural insights into broad neutralization of hepatitis C virus by human V(H)1-69 antibodies
por: Tzarum, Netanel, et al.
Publicado: (2019)

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
por: Velázquez-Moctezuma, Rodrigo, et al.
Publicado: (2017)

From Structural Studies to HCV Vaccine Design
por: Yechezkel, Itai, et al.
Publicado: (2021)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein
por: Tzarum, Netanel, et al.
Publicado: (2018)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus
por: Olesen, Christina Holmboe, et al.
Publicado: (2021)

Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines
por: He, Linling, et al.
Publicado: (2020)

Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry
por: Prentoe, Jannick, et al.
Publicado: (2018)

Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate
por: Keck, Zhen-yong, et al.
Publicado: (2012)

Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies
por: Velázquez-Moctezuma, Rodrigo, et al.
Publicado: (2021)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens
por: Prentoe, Jannick, et al.
Publicado: (2021)

Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity
por: Augestad, Elias H., et al.
Publicado: (2020)

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design
por: Keck, Zhen-Yong, et al.
Publicado: (2019)

Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis
por: Gopal, Radhika, et al.
Publicado: (2017)

Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers
por: Prentoe, Jannick, et al.
Publicado: (2022)

Hepatitis C Virus (HCV)–Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design
por: Wrensch, Florian, et al.
Publicado: (2018)

Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1–7 in Infectious Cell Culture Systems
por: Scheel, Troels K. H., et al.
Publicado: (2012)

Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
por: Czarnota, Anna, et al.
Publicado: (2020)

Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape
por: Krey, Thomas, et al.
Publicado: (2013)

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
por: Pihl, Anne F., et al.
Publicado: (2018)

A Meta-Analysis of the Existing Knowledge of Immunoreactivity against Hepatitis C Virus (HCV)
por: Kim, Yohan, et al.
Publicado: (2012)

A structured RNA motif locks Argonaute2:miR-122 onto the 5’ end of the HCV genome
por: Gebert, Luca F. R., et al.
Publicado: (2021)

The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae
por: Stapleton, Jack T., et al.
Publicado: (2011)

Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding
por: He, Linling, et al.
Publicado: (2015)

Antibodies against viruses: passive and active immunization
por: Law, Mansun, et al.
Publicado: (2008)

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
por: Christiansen, D., et al.
Publicado: (2018)

Neutralizing Antibody Response to Hepatitis C Virus
por: Wang, Yong, et al.
Publicado: (2011)

Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains
por: Dreux, Marlène, et al.
Publicado: (2009)

Impact of the Autophagy Machinery on Hepatitis C Virus Infection
por: Dreux, Marlène, et al.
Publicado: (2011)

Regulation of the Host Antiviral State by Intercellular Communications
por: Assil, Sonia, et al.
Publicado: (2015)

Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model
por: Galli, Andrea, et al.
Publicado: (2018)

HCV p7 as a novel vaccine-target inducing multifunctional CD4(+) and CD8(+) T-cells targeting liver cells expressing the viral antigen
por: Filskov, Jonathan, et al.
Publicado: (2019)

Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus
por: Fuerst, Thomas R., et al.
Publicado: (2018)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine
por: Keck, Mei-Le, et al.
Publicado: (2018)

Interplay between SARS-CoV-2 and the type I interferon response
por: Sa Ribero, Margarida, et al.
Publicado: (2020)

An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development
por: Salas, Jordan H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_41g8olufo486l7khqlgivmtan6